Researchers examined Medline, EMBASE and the Cochrane controlled trials registry and assessed the following cardiopulmonary adverse events: hypoxia, hypotension and arrhythmias. The procedures were divided into two groups based on the procedure length — a non-advanced endoscopic procedure group and an advanced endoscopic procedures group. Twenty-seven original studies, including 2,518 patients, qualified for the meta-analysis. Of the 2,518 patients, 1,324 received propofol and 1,194 received midazolam, meperidine, pethidine, remifentanil and/or fentanyl.
Here are four insights:
1. Compared with traditional sedative agents, the pooled odds ratio with the use of propofol for developing hypoxia for all the procedures combined was 0.82. The pooled odds ratio for developing hypotension was 0.92.
2. In the non-advanced endoscopic procedure group, those who received propofol were 39 percent less likely to develop complications than those receiving traditional anesthetic agents.
3. There was no difference in the complication rate for the advanced endoscopic procedures group.
4. A sub-group analysis did not show any difference in adverse events when propofol was administered.
More articles on GI/endoscopy:
5 most read GI/endoscopy stories: July 18 — 22
Schizophrenic son of gastroenterologist Dr. William Wu found guilty of stabbing him: 5 notes
LifeBond’s surgical sealant kit receives FDA IDE approval: 4 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.